medigraphic.com
ISSN 1684-1824 (Digital)

2015, Número 4

<< Anterior Siguiente >>

Rev Méd Electrón 2015; 37 (4)


Dosificación de la aspirina en el síndrome coronario agudo

Arredondo BAE, Acuña SJA, Arredondo RAE

Idioma: Español
Referencias bibliográficas: 31
Paginas: 364-373
Archivo PDF: 78.44 Kb.


RESUMEN

Introducción: se han publicado escasos ensayos clínicos que prueban la eficacia de la aspirina en la prevención secundaria de la enfermedad cardiovascular. Se presentó una revisión de la literatura publicada recientemente acerca de la dosis de la aspirina en los pacientes del síndrome coronario agudo.
Resultados: los ensayos clínicos, bien documentados, que evalúan la eficacia comparativa de las diferentes dosis de aspirina son muy escasos en la literatura mundial.
Discusión: esta compleja terapia antiplaquetaria hace muy difícil el poder identificar la dosis exacta de la aspirina, para obtener los mejores resultados con eficacia y minimizar los riesgos de eventos adversos, obedeciendo a varias pautas y recomendaciones.
Conclusiones: a pesar de este hecho, la evidencia actual sugiere que las dosis de la aspirina de 75-100 mg/día pueden ofrecer una proporción beneficio/riesgo óptima en pacientes con síndrome coronario agudo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1- Boon N, Boyle R., Bradbury K, Buckley J, Connolly S, Craig S,Wood D. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014;100(Suppl 2). Citado en PubMed; PMID: 24667225.

  2. 2- DiNicolantonio JJ, Norgard NB, Meier P, Lavie CJ, O'Keefe JH, Niazi AK, et al. Optimal Aspirin Dose in Acute Coronary Syndromes. Future Cardiol. 2014;10(2):291-300. Citado en PubMed; PMID: 24762255.

  3. 3- Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638-45. Citado en PubMed; PMID: 20609686.

  4. 4- Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. J Am Coll Cardiol. 1988;12(6 Suppl A):3A-13A. Citado en PubMed; PMID: 2903874.

  5. 5- Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60. Citado en PubMed; PMID: 19482214.

  6. 6- Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond. Circulation. 2010;121(4):586-613. Citado en PubMed; PMID: 20089546.

  7. 7- O'Brien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR, et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2014;167(4):601-9. Citado en PubMed; PMID: 24655711.

  8. 8- Baigent C, Sudlow C, Collins R, Peto R. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329):71-86. Citado en PubMed; PMID: 11786451.

  9. 9- Harjai KJ, Shenoy C, Orshaw P, Usmani S, Singh M, Boura J, et al. Low-dose versus high-dose aspirin after percutaneous coronary intervention: analysis from the guthrie health off-label StenT (GHOST) registry. J Interv Cardiol. 2011;24(4):307-14. Citado en PubMed; PMID: 21790788.

  10. 10- Berger JS, Sallum RH, Katona B, Maya J, Ranganathan G, Xu Y, et al. Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. Am Heart J. 2012; 164(2):153-62. Citado en PubMed; PMID: 22877800.

  11. 11- Husted SE, Kraemmer Nielsen H, Krusell LR. Acetylsalicylic acid 100 mg and 1000 mg daily in acute myocardial infarction suspects: a placebo-controlled trial. J Intern Med. 1989;226(5):303-10. Citado en PubMed; PMID: 2681509.

  12. 12- Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, et al. Primary and secondary prevention of cardiovascular disease. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl.):637S-68S. Citado en PubMed; PMID: 22315274.

  13. 13- O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):529-55. Citado en PubMed; PMID: 23247303.

  14. 14- CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363(10):930-42. Citado en PubMed; PMID: 20818903.

  15. 15- Spectre G, Arnetz L, Östenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with Type 2 diabetes mellitus and micro- or macrovascular complications. Thromb. Haemost. 2011;106(3): 491-9. Citado en PubMed; PMID: 21800009.

  16. 16- Dillinger JG, Drissa A, Sideris G, Bal dit Sollier C, Voicu S, Manzo Silberman S, et al. Biological efficacy of twice daily aspirin in Type 2 diabetic patients with coronary artery disease. Am Heart J. 2012;164(4):600-6. Citado en PubMed; PMID: 23067920.

  17. 17- Addad F, Chakroun T, Elalamy I, Abderazek F, Chouchene S, Dridi Z, et al. Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. Int J Hematol. 2010;92(2):296-301. Citado en PubMed; PMID: 20725815.

  18. 18- 2012 Writing Committee Members, Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2012;126(7):875-910. Citado en PubMed; PMID: 22800849.

  19. 19- Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23):574-651. Citado en PubMed; PMID: 22064598.

  20. 20- Kohli P, Udell J, Murphy S, Cannon CP, Antman EM, Braunwald E, et al. Discharge aspirin dose and clinical outcomes in patients with ACS: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). J Am Coll Cardiol. 2014;63(3):225-332. Citado en PubMed; PMID: 24140678.

  21. 21- Jolly SS, Pogue J, Haladyn K, Peters RJ, Fox KA, Avezum A, et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J. 2009;30(8):900-7. Citado en PubMed; PMID: 18819961.

  22. 22- Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376(9748): 1233-43. Citado en PubMed; PMID: 20817281.

  23. 23- Berger JS, Brown DL, Burke GL, Oberman A, Kostis JB, Langer RD, et al. Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study. Circ Cardiovasc Qual Outcomes. 2009;2(2):78-87. Citado en PubMed; PMID: 20031819.

  24. 24- Mehta SR, Van de Werf F. A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes. Barcelona: European Society of Cardiology European Congress; 2009 .

  25. 25- Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124(5):544-54. Citado en PubMed; PMID: 21709065.

  26. 26- DiNicolantonio JJ, Serebruany VL. Challenging the FDA black box warning for high aspirin dose with ticagrelor in patients with diabetes. Diabetes. 2013;62(3):669-71. Citado en PubMed; PMID: 23431005.

  27. 27- Administration UFaD. FDA ticagrelor review of complete response - drug approval package [Internet]. USA: US Department of Health & Human Services; 2011 [citado 15 Ene 2015]. Disponible en: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000MedR.pdf

  28. 28- Armstrong PC, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemos. 2011;9(3):552-61. Citado en PubMed; PMID: 21143373.

  29. 29- Bhavaraju K, Georgakis A, Jin J, Gartner TK, Tomiyama Y, Nurden A, et al. Antagonism of P2Y12 reduces physiological thromboxane levels. Platelets. 2010;21(8):604-9. Citado en PubMed; PMID: 21067313.

  30. 30- Leadbeater PD, Kirkby NS, Thomas S, Dhanji AR, Tucker AT, Milne GL, et al. Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. JThromb Haemost. 2011;9(10):2050-6. Citado en PubMed; PMID: 21794076.

  31. 31- Kirkby NS, Leadbeater PD, Chan MV, Nylander S, Mitchell JA, Warner TD. Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost. 2011;9(10):2103-5. Citado en PubMed; PMID: 21812912.




2020     |     www.medigraphic.com